Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Issues Guidance on Clinical Trial Design for Radiopharmaceuticals
August 4, 2025
- Wage-Based Price Premiums on Drugs Not an Option, Says MHLW Insurance Chief
August 4, 2025
- Japan Panel OKs Taisho’s Insomnia Med, 2 Other NMEs for Approval
August 1, 2025
- MHLW Selects 20 Organizations to Bolster Drug Discovery Clusters
August 1, 2025
- MHLW Orders Label Revisions for Semaglutide, Tirzepatide to Include Ileus Risk
July 31, 2025
- 23 Suspected Promotional Violations Identified for 18 Drugs in FY2024: MHLW
July 31, 2025
- MHLW Panel to Further Review Positioning of Susmed’s Insomnia App
July 31, 2025
- MHLW to Link GS1 and YJ Codes in Public Database, Launch Planned for FY2028
July 30, 2025
- MHLW Raises Drug R&D, Supply Stability as FY2026 Budget Priorities
July 30, 2025
- OTC-Like Drugs Flagged as Key Agenda Item by CEFP Members
July 29, 2025
- Post-Marketing Oversight and Regulatory Reviews Must Work as One, Says New MHLW Safety Chief
July 29, 2025
- Astellas Employee Did Not Appeal, Prison Sentence Finalized in China
July 29, 2025
- Japan Panel Urges Consolidation of Cancer Surgery, Radiotherapy amid Shrinking Surgeon Workforce
July 29, 2025
- Two Oral Drugs Found to Exceed ADI for Red No. 3, MHLW Reports
July 28, 2025
- PMDA Launches Advisory Program for Academia, Startups Developing New Modalities
July 28, 2025
- MSD’s 21-Valent Pneumococcal Shot Nears Japan Approval; Male Use of Silgard 9 Cleared
July 25, 2025
- Santen’s Glaucoma Drug, Taisho’s Insomnia Med Up for Panel Review on July 31
July 25, 2025
- MHLW Calls for Ongoing Nitrosamine Risk Controls after Self-Inspections
July 24, 2025
- 223 Health Damages Reported for Breyanzi in Japan: October-March
July 24, 2025
- MHLW Plans to Ease Clinical Trial Ad Rules, Eyes Notification by March-End
July 24, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…